Holmium Laser Enucleation of the Prostate: Results at 6 Years

ObjectivesThe issue of durability is an important concern when evaluating new surgical modalities. To date, only 24-mo data have been published on holmium enucleation of the prostate (HoLEP) despite its widespread use worldwide although 4-yr data exist for the earlier technique of holmium resection. This study addresses the issue of durability of HoLEP.MethodsAll patients who had undergone HoLEP and been evaluated in three prospective trials conducted at this institution between 1997 and 2002 were evaluated. Patients available at follow-up had data assessed on the International Prostate Symptom Score (IPSS), maximal flow rate (Qmax), quality of life (QOL), International Continence Society Male Short Form (ICS-SF), International Index of Erectile Function (IIEF), Benign Prostatic Hyperplasia Impact Index (BPHII), and continence questionnaire.ResultsThe mean follow-up was 6.1 yr (range: 4.1–8.1 yr). The mean age of the patients at follow-up was 75.7 yr (range: 58–88 yr). Of 71 HoLEP patients originally studied on the protocol, 38 (54%) were available for analysis, 14 were deceased, and 19 were lost to follow-up. The mean IPSS for this group was 8.5 (range: 0–24) and Qmax 19 ml/s (range: 6–28 ml/s). The QOL score was 1.8 (range: 0–5) and the BPHII 2.0 (range: 0–11). One patient (1.4%) had undergone reoperation, an additional HoLEP. Overall, 92% were either satisfied or extremely satisfied with their outcome.ConclusionsHoLEP is durable and most patients remain satisfied or extremely satisfied with the long-term outcome.